about
European guidance for the diagnosis and management of osteoporosis in postmenopausal womenNew perspectives in echographic diagnosis of osteoporosis on hip and spinePrediction of fracture risk in patients with osteoporosis: a brief reviewA Guide to Improving the Care of Patients with Fragility Fractures, Edition 2A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation.In Vivo Quantitative MR Imaging of Bound and Pore Water in Cortical Bone.MRI-derived bound and pore water concentrations as predictors of fracture resistanceAdvances in imaging approaches to fracture risk evaluation.FRAX®: prediction of major osteoporotic fractures in women from the general population: the OPUS study.External validation and comparison of three prediction tools for risk of osteoporotic fractures using data from population based electronic health records: retrospective cohort study.Vertebral fractures and self-perceived health in elderly women and men in a population-based cross-sectional study: the Tromsø Study 2007-08Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone scoreEpidemiology of hip fracture and the development of FRAX in Ukraine.Osteoporosis prevention, screening, and treatment: a review.Osteoporosis, fractures, and diabetes.Calibration of FRAX ® 3.1 to the Dutch population with data on the epidemiology of hip fracturesImportant risk factors and attributable risk of vertebral fractures in the population-based Tromsø study.Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA.The discriminative ability of FRAX, the WHO algorithm, to identify women with prevalent asymptomatic vertebral fractures: a cross-sectional study.unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance?Management of severe osteoporosis.A simple score for estimating the long-term risk of fracture in patients with multiple sclerosis.Potential Extensions of the US FRAX Algorithm.Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.Assessing Risk of Osteoporotic Fractures in Primary Care: Development and Validation of the FRA-HS Algorithm.Development and Validation of Osteoporosis Risk-Assessment Model for Korean MenWhen the FRAX(®) test is applied to controlled clinical trials.Effect of including historical height and radius BMD measurement on sarco-osteoporosis prevalenceClinical risk factors, bone density and fall history in the prediction of incident fracture among men and women.Health technology assessment in osteoporosis.Risk of major osteoporotic fracture after cardiovascular disease: a population-based cohort study in TaiwanGeographic differences in fractures among women.Use of FRAX(®) in men.A Comprehensive Fracture Prevention Strategy in Older Adults: The European Union Geriatric Medicine Society (EUGMS) Statement.Fracture risk assessment in postmenopausal women referred to an Italian center for osteoporosis: a single day experience in Messina.Conflicts at the heart of the FRAX tool.Is there a specific fracture 'cascade'?New horizons in treatment of osteoporosis.Melatonin-micronutrients Osteopenia Treatment Study (MOTS): a translational study assessing melatonin, strontium (citrate), vitamin D3 and vitamin K2 (MK7) on bone density, bone marker turnover and health related quality of life in postmenopausal osStudy of DXA-derived lateral-medial cortical bone thickness in assessing hip fracture risk.
P2860
Q24612411-9770F1A9-9FAD-4041-A5D0-FB7F1ADC1090Q26775752-138CA3FE-E427-465F-BE16-1EFCC86E6703Q26799776-8CC93966-D019-4A67-8F12-023D42A5B33DQ28647551-7EE04DC8-074A-45F2-A5BE-F9C9533B8DBBQ30248756-B6CDCC6F-A2F9-41B2-B1E3-C02BE1FC202CQ30960498-A8FE114D-2C43-4A7C-9EA9-33BC83900873Q31060711-9A504BD6-5D40-443A-BCA2-2ED96F1ADCF5Q31141102-DE6FF1B2-AF33-4D68-9080-40E034B82BC3Q31147039-A4BBC571-3A77-4431-8189-18CDD4C779BCQ31155466-5AFF5E9A-314E-4B98-BA90-977B7EE5C5B7Q33590070-C8B8338D-7176-43D3-86AD-7CC4D9C75487Q33792517-2742A031-839A-4773-84BD-AEFC42488250Q33841213-0EC685A2-2CB2-45B1-92F8-33C02F35BBA7Q33870810-82CD29A8-7DBF-43A3-9D54-FE878349DD06Q33891378-5827E95D-2490-43EF-8C05-F2E950B739F1Q34084507-7954B398-E998-4D62-9DAE-2685D5E9C4DBQ34398142-6189CA84-5069-4487-8A0D-6A53B6AB441DQ34459547-FAF66501-7F09-4F24-A1CD-D0EF24BA8599Q34484663-0BCD730E-3BA0-4CDB-83FB-3FA55A68C691Q34718186-E89BDECD-6528-4C24-B777-3BE968E6C050Q35852252-817A1315-EE7B-4483-8635-FCF143257280Q36183795-9D4BAF44-8DD5-4D5A-89F7-1C266864198DQ36184831-F0E85988-F9EB-4AB8-9CF8-93AD736263D6Q36187103-60EE6A9F-07CB-408D-806F-D168059EF900Q36270538-2977BE17-4FD0-4360-B89A-A1A56F4D6CF7Q36418698-CF231A75-0A7E-45CA-9E70-F8EE3BDDAD1DQ36505613-E4AF4106-F56F-437F-9D3B-DA1CB2DBF9FBQ36636415-A9C30099-197F-42F5-8524-EFC1A39CA64EQ36845915-62046FC9-BD4B-4DFD-9DC9-6EE934D310B1Q36965411-56645245-D054-457C-8823-388EE87DE7E4Q36978768-A80A7ADD-C150-440D-A61A-B72F1DC98E31Q37077317-73965FD0-C57D-4849-B373-5800DA428B73Q37296607-E5365A0C-46FE-4639-9B78-CA0A188EF2F5Q37392405-37E06477-9362-440D-909D-30B40FD1BE60Q37567203-9E0DAB33-91FA-4A0A-AEB0-6AE569048807Q37591552-FF8C3EE7-69F4-4CBC-A67B-4E2E9DD6AB9AQ37604107-FAD73142-04CD-4440-B5D3-E803B21F3BD6Q37630995-D6E8E012-2BB1-451C-904E-D1FBC5C1836BQ37643521-A6C88799-C53C-4D9A-9144-AF8FA2C5EE5BQ37720408-160D39D7-01F6-44E4-BA1B-32B2F9FDFA12
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Interpretation and use of FRAX in clinical practice.
@en
Interpretation and use of FRAX in clinical practice.
@nl
type
label
Interpretation and use of FRAX in clinical practice.
@en
Interpretation and use of FRAX in clinical practice.
@nl
prefLabel
Interpretation and use of FRAX in clinical practice.
@en
Interpretation and use of FRAX in clinical practice.
@nl
P2093
P2860
P50
P1476
Interpretation and use of FRAX in clinical practice.
@en
P2093
B Dawson-Hughes
E M Lewiecki
E V McCloskey
G El-Hajj Fuleihan
H Johansson
P2860
P2888
P304
P356
10.1007/S00198-011-1713-Z
P407
P577
2011-07-21T00:00:00Z